<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114401">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02024867</url>
  </required_header>
  <id_info>
    <org_study_id>DB 2456</org_study_id>
    <nct_id>NCT02024867</nct_id>
  </id_info>
  <brief_title>Efficacy Study of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage</brief_title>
  <official_title>Randomized Trial of 3 Versus 10 Days of Trimethoprim-Sulfamethoxazole in Community-Associated Skin Abscesses After Surgical Drainage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lucy Holmes, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New York State Department of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Women &amp; Children's Hospital of Buffalo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine if there is a difference in treatment failures
      between 3 and 10 days of antibiotics for uncomplicated skin abscesses after they have been
      surgically drained.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of treatment failures in 3 versus 10 day antibiotic groups</measure>
    <time_frame>up to 2 weeks after surgical drainage</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of new lesions in index patient in 3 versus 10 day antibiotic groups</measure>
    <time_frame>monthly, up to 6 months after surgical drainage</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new lesions in household contacts in 3 versus 10 day antibiotic groups</measure>
    <time_frame>monthly, up to 6 months after surgical drainage</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with side effects from antibiotics in 3 versus 10 day treatment groups</measure>
    <time_frame>up to 2 weeks after surgical drainage</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">281</enrollment>
  <condition>Skin Disease, Bacterial</condition>
  <condition>Abscess</condition>
  <arm_group>
    <arm_group_label>10 days of Trimethoprim-Sulfamethoxazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trimethoprim-Sulfamethoxazole dosed at 5 mg Trimethoprim/kg/dose twice a day, to a maximum of 320 mg Trimethoprim/dose twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 days of Trimethoprim-Sulfamethoxazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trimethoprim-Sulfamethoxazole dosed at 5 mg Trimethoprim/kg/dose twice a day, to a maximum of 320 mg Trimethoprim/dose twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim-Sulfamethoxazole</intervention_name>
    <arm_group_label>10 days of Trimethoprim-Sulfamethoxazole</arm_group_label>
    <arm_group_label>3 days of Trimethoprim-Sulfamethoxazole</arm_group_label>
    <other_name>Septra</other_name>
    <other_name>Bactrim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients presenting with a skin abscess that requires surgical drainage (induration
             greater than 2 cm in diameter)

          -  minimally invasive surgical technique with the insertion of a subcutaneous drain can
             be utilized on the patient

        Exclusion Criteria:

          -  patients requiring immediate hospitalization

          -  patients who have received 2 or more doses of antibiotics in the previous 36 hours

          -  patients with diabetes, sickle-cell disease, an immuno-compromising disease, an
             underlying medical condition predisposing the patient to frequent hospitalizations or
             medical visits, or indwelling catheters or percutaneous medical devices

          -  patients with a concurrent, different, additional infection

          -  patients with an allergy to Trimethoprim-sulfamethoxazole
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucy C Holmes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howard Faden, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women &amp; Children's Hospital of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Duong M, Markwell S, Peter J, Barenkamp S. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med. 2010 May;55(5):401-7. Epub 2009 May 5.</citation>
    <PMID>19409657</PMID>
  </reference>
  <reference>
    <citation>Schmitz GR, Bruner D, Pitotti R, Olderog C, Livengood T, Williams J, Huebner K, Lightfoot J, Ritz B, Bates C, Schmitz M, Mete M, Deye G. Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection. Ann Emerg Med. 2010 Sep;56(3):283-7. doi: 10.1016/j.annemergmed.2010.03.002. Epub 2010 Mar 26. Erratum in: Ann Emerg Med. 2010 Nov;56(5):588.</citation>
    <PMID>20346539</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 27, 2013</lastchanged_date>
  <firstreceived_date>December 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York at Buffalo</investigator_affiliation>
    <investigator_full_name>Lucy Holmes, MD</investigator_full_name>
    <investigator_title>Clinical Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Methicillin resistent Staphylococcus aureus</keyword>
  <keyword>Staphylococcus aureus</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abscess</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Skin Diseases, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim-Sulfamethoxazole Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
